Following to the acquisition of the operating subsidiaries of Invent Farma and neuraxpharm, the new group was created under the name NuPharm Group
The NuPharm Group has been created with the vision to be the European leader in pharmaceutical products for the treatment of the central nervous system (CNS) by offering a wide range of proven, differentiated and affordable CNS treatment options to patients, healthcare professionals and industry partners.
The Group is a strategic combination of leading and experienced European pharmaceutical companies with outstanding development, manufacturing and sales capabilities focused on CNS. NuPharm hasĀ four companies neuraxpharm, Qualigen, Laboratorios Lesvi and Inke.
Its dedicated sales presence commercializes branded CNS products and INN generics in Europe. Additionally, the Group also manufactures finished dosage forms (FDFs) and niche active pharmaceutical ingredients (APIs) in the CNS and the respiratory areas.